Physician profile
Michael A Day
NPI 1922008317
$339.82
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $64.91 · 2021: $11.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.35 | 2019-2020 | |
| Astellas Pharma US INC | $45.33 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.28 | 2019 | |
| Pfizer INC. | $40.71 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $27.85 | 2019 | |
| Genentech USA, INC. | $23.91 | 2020-2021 | |
| Ethicon US, LLC | $21.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2019 | |
| Lilly USA, LLC | $14.37 | 2019 | |
| Boston Scientific Corporation | $13.87 | 2019 | |
| Novo Nordisk INC | $12.84 | 2019 | |
| Akcea Therapeutics, INC. | $11.65 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.